C-reactive protein (CRP) is a sensitive marker of systemic inflammation produced by the liver in response to inflammatory stimuli. Whilst CRP levels are widely used to assess infection and chronic inflammatory states, their role in fatty liver disease is less well defined. Emerging evidence suggests an association between elevated CRP and non-alcoholic fatty liver disease (NAFLD), reflecting the complex interplay between metabolic dysfunction, hepatic inflammation, and systemic inflammatory responses. However, CRP is not part of recommended UK pathways for diagnosing or staging NAFLD. This article examines the relationship between CRP and fatty liver disease, exploring the mechanisms linking inflammation to hepatic steatosis and clarifying CRP's limited clinical utility in NAFLD assessment.

What Is C-Reactive Protein and Why Does It Matter?

C-reactive protein (CRP) is an acute-phase reactant synthesised primarily by hepatocytes in the liver in response to inflammatory stimuli. This pentameric protein serves as a sensitive, though non-specific, biomarker of systemic inflammation and tissue damage. CRP levels rise rapidly—often within 6 to 8 hours—following an inflammatory insult, making it a valuable tool for detecting and monitoring inflammatory processes throughout the body.

In clinical practice, CRP measurement is widely used to assess infection, autoimmune conditions, cardiovascular risk, and chronic inflammatory states. Standard CRP assays used in UK laboratories typically report reference ranges below 5–10 mg/L in healthy adults, though ranges may vary slightly between laboratories. High-sensitivity CRP (hs-CRP) assays can detect lower concentrations (typically 0.5–10 mg/L) and use different thresholds (<1, 1–3, >3 mg/L) primarily in research contexts; however, NICE does not recommend routine hs-CRP testing for cardiovascular risk assessment in the UK, where QRISK tools are the standard.

Elevated CRP indicates an active inflammatory process but does not identify the specific cause or location of inflammation, necessitating clinical correlation and further investigation. It is important to note that CRP is produced by the liver but is not a standard marker of hepatic synthetic function—albumin and prothrombin time (INR) serve that purpose. In severe hepatic failure, the liver's capacity to produce CRP may be impaired, potentially blunting the inflammatory response.

The significance of CRP extends beyond acute illness. Persistently elevated CRP levels have been associated with increased cardiovascular risk and metabolic dysfunction in observational studies. In the context of liver disease, CRP reflects systemic inflammation that may accompany liver pathology, though it is not part of recommended pathways for diagnosing or staging non-alcoholic fatty liver disease (NAFLD) in UK guidance. Understanding CRP's role as a non-specific inflammatory marker is essential for clinicians, but validated non-invasive fibrosis tests—not CRP—should guide NAFLD assessment and monitoring.

The Link Between CRP and Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the term currently used in UK clinical practice (NICE guidance), though the evolving nomenclature metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised internationally. NAFLD represents a spectrum of conditions characterised by hepatic steatosis in the absence of significant alcohol consumption, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which involves inflammation and hepatocyte injury, potentially progressing to fibrosis, cirrhosis, and hepatocellular carcinoma.

Emerging observational evidence demonstrates an association between elevated CRP levels and the presence and severity of fatty liver disease. Multiple studies have shown that individuals with NAFLD exhibit higher circulating CRP concentrations compared to those without hepatic steatosis, even after adjusting for body mass index and other metabolic factors. However, this relationship is complex and likely reflects shared underlying metabolic dysfunction, adiposity, and insulin resistance rather than a simple causal pathway. Hepatic steatosis is associated with systemic inflammation, whilst chronic inflammation may contribute to the development and progression of liver disease, but causality and bidirectionality remain incompletely understood.

The mechanistic link involves several pathways. Adipose tissue dysfunction, particularly visceral adiposity commonly seen in NAFLD patients, leads to increased secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). These cytokines stimulate hepatic CRP production whilst simultaneously promoting hepatic lipid accumulation and insulin resistance. Additionally, the inflamed, fatty liver itself may become a source of inflammatory mediators, creating a cycle of metabolic dysfunction and inflammation.

CRP levels have been observed to correlate modestly with disease severity in some NAFLD studies. Patients with NASH may demonstrate higher CRP concentrations than those with simple steatosis, and CRP elevation has been associated with advanced fibrosis in some cohorts. However, CRP is not part of diagnostic criteria for NAFLD or NASH, and there are no validated CRP thresholds to distinguish between disease stages. NICE and British Society of Gastroenterology (BSG) guidance recommend validated non-invasive fibrosis tests—such as FIB-4, NAFLD Fibrosis Score (NFS), and Enhanced Liver Fibrosis (ELF) test—rather than inflammatory markers like CRP for risk stratification and staging.

How Elevated CRP Levels Indicate Liver Inflammation

Elevated CRP in the context of fatty liver disease reflects the complex interplay between hepatic inflammation, metabolic dysfunction, and systemic inflammatory responses. In NASH, hepatocyte injury triggers an inflammatory cascade involving resident liver macrophages (Kupffer cells), recruited immune cells, and hepatic stellate cells. This inflammatory milieu generates cytokines that stimulate CRP synthesis, making CRP a non-specific surrogate marker for systemic and hepatic inflammation.

The pathophysiology involves multiple cellular and molecular mechanisms. Lipotoxicity—the accumulation of toxic lipid species within hepatocytes—induces oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction. These processes activate inflammatory signalling pathways, including nuclear factor-kappa B (NF-κB), leading to production of IL-6 and other cytokines that directly stimulate CRP gene expression in hepatocytes. Simultaneously, gut-derived endotoxins (lipopolysaccharides) may reach the liver via portal circulation in patients with increased intestinal permeability, further amplifying inflammatory responses. (Note: cytokine measurements such as IL-6 and TNF-α are research tools and not used in routine UK clinical practice.)

CRP elevation in fatty liver patients often occurs alongside other inflammatory markers, including elevated white cell count and erythrocyte sedimentation rate (ESR). CRP's relatively short half-life (approximately 19 hours) and rapid response to inflammatory changes make it useful for monitoring acute inflammatory activity. Studies have demonstrated modest and variable correlations between CRP levels and histological features of NASH, including lobular inflammation and hepatocyte ballooning. However, this correlation is insufficient for CRP to replace liver biopsy or validated non-invasive fibrosis tests in diagnosis or staging, as emphasised in EASL and NICE guidance.

It is important to recognise that CRP elevation in fatty liver patients is not specific to liver inflammation alone. These patients frequently have multiple comorbidities—including obesity, type 2 diabetes, and cardiovascular disease—that independently contribute to systemic inflammation and CRP elevation. Additionally, in advanced cirrhosis, the liver's capacity to produce CRP may be impaired, so a low or normal CRP does not exclude infection or inflammation in patients with severe hepatic dysfunction. Therefore, interpreting CRP results requires careful consideration of the patient's overall clinical picture and exclusion of other inflammatory conditions.

Testing and Interpreting CRP in Fatty Liver Patients

CRP testing in patients with suspected or confirmed fatty liver disease may form part of a broader assessment of inflammation and comorbidity, but it is not recommended by NICE or BSG guidance for diagnosing or staging NAFLD. Standard CRP assays measure concentrations typically in the range of 5–10 mg/L and above, whilst high-sensitivity CRP (hs-CRP) assays can quantify lower concentrations; however, hs-CRP is not routinely recommended in UK practice for cardiovascular risk assessment (NICE uses QRISK tools) or for NAFLD monitoring.

When CRP tests are ordered, clinicians should consider the clinical context and timing. CRP levels can be transiently elevated by acute infections, recent surgery, trauma, or other inflammatory conditions unrelated to liver disease. Testing should ideally occur when patients are clinically stable, and unexpectedly high results should prompt investigation for concurrent acute illness. Very high CRP levels (typically >100 mg/L) more strongly suggest bacterial infection and require urgent clinical assessment. Serial measurements over time provide more valuable information than single readings, helping to distinguish chronic elevation from transient fluctuations.

Interpretation of CRP results in fatty liver disease requires integration with other investigations. NICE guidance (NG49) on NAFLD assessment recommends a comprehensive, stepwise approach:

• Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin, prothrombin time/INR). Important: normal liver enzymes do not exclude NAFLD or advanced fibrosis.

• Metabolic markers (fasting glucose, HbA1c, lipid profile)

• First-line non-invasive fibrosis risk stratification using FIB-4 or NAFLD Fibrosis Score (NFS), with age-specific thresholds (e.g., FIB-4 <1.3 suggests low risk in adults <65 years; <2.0 in those ≥65 years)

• Second-line testing with Enhanced Liver Fibrosis (ELF) test if first-line scores are indeterminate or suggest increased risk

• Imaging studies (ultrasound to detect steatosis; transient elastography/FibroScan may be used in specialist settings)

• Assessment of cardiovascular risk factors using QRISK

CRP should not be used to diagnose NASH or to distinguish simple steatosis from steatohepatitis. There are no validated CRP thresholds for this purpose in UK guidance. Persistently elevated CRP in a patient with confirmed hepatic steatosis may reflect systemic inflammation associated with metabolic syndrome and comorbidities, but risk stratification and monitoring should rely on validated non-invasive fibrosis tests as outlined above.

Patient management focuses on addressing modifiable risk factors. Lifestyle interventions—including weight loss of 7–10% body weight, increased physical activity, and dietary modification—remain the cornerstone of NAFLD management and have been shown to reduce both hepatic steatosis and systemic inflammation. Patients should be advised that:

• Weight loss through caloric restriction and exercise can significantly reduce liver fat and inflammation

• Mediterranean-style diets may confer particular benefits

• Alcohol consumption should follow UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units per week, spread over at least 3 days, with several alcohol-free days); individuals with steatohepatitis or fibrosis should consider abstinence

• Optimal management of diabetes, hypertension, and dyslipidaemia is essential

There are currently no medicines licensed in the UK specifically for the treatment of NAFLD. Management focuses on lifestyle modification and optimisation of cardiometabolic risk factors. Any pharmacological interventions for liver disease should be under specialist hepatology supervision.

Referral to specialist hepatology services should be considered for patients with:

• Evidence of advanced fibrosis based on non-invasive scores (e.g., high FIB-4/NFS or elevated ELF)

• Persistently elevated liver enzymes despite lifestyle modification

• Diagnostic uncertainty or suspicion of alternative/additional liver pathology

• Signs of decompensated liver disease or portal hypertension

Patients with markedly elevated CRP alongside other concerning features—such as progressive liver dysfunction, unexplained weight loss, or clinical signs of advanced liver disease—require urgent specialist assessment.

Monitoring intervals should follow NICE NG49 guidance and depend on fibrosis risk. Adults with NAFLD and low initial fibrosis risk (based on FIB-4/NFS) may be considered for retesting of advanced fibrosis risk approximately every 3 years. Those with indeterminate or high-risk scores, significant comorbidities, or progressive disease require more frequent specialist review, typically every 6–12 months. CRP is not recommended as a routine monitoring tool for NAFLD progression; follow-up should focus on validated non-invasive fibrosis tests, liver enzymes, metabolic parameters, and cardiovascular risk assessment using QRISK.

Frequently Asked Questions